Education
About Us
Working with TipRanks
Follow Us
GlaxoSmithKline (GSK)
NYSE:GSK
GSK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$31.72 - $45.93
Previous CloseN/A
Volume981.79K
Average Volume (3M)5.89M
Market Cap
$77.74B
Enterprise Value$97.49B
Total Cash (Recent Filing)£4.46B
Total Debt (Recent Filing)£0.00
Price to Earnings (P/E)24.2
Beta0.24
Next Earnings
Jul 30, 2025EPS Estimate
1.15Next Dividend Ex-Date
May 16, 2025Dividend Yield3.92%
Share Statistics
EPS (TTM)1.95
Shares Outstanding2,054,865,700
10 Day Avg. Volume5,730,724
30 Day Avg. Volume5,893,429
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$40.08Price Target Upside2.59% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Ownership Overview
―
Insiders
5.77% Mutual Funds
0.91% Other Institutional Investors
93.07% Public Companies and
Individual Investors
GSK FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
GlaxoSmithKline lowest stock price was $31.71 and its highest was $45.92 in the past 12 months.
What is GlaxoSmithKline’s market cap?
GlaxoSmithKline’s market cap is $77.74B.
When is GlaxoSmithKline’s upcoming earnings report date?
GlaxoSmithKline’s upcoming earnings report date is Jul 30, 2025 which is in 87 days.
How were GlaxoSmithKline’s earnings last quarter?
GlaxoSmithKline released its earnings results on Apr 30, 2025. The company reported $1.199 earnings per share for the quarter, beating the consensus estimate of $1.045 by $0.154.
Is GlaxoSmithKline overvalued?
According to Wall Street analysts GlaxoSmithKline’s price is currently Undervalued.
Does GlaxoSmithKline pay dividends?
GlaxoSmithKline pays a Quarterly dividend of $0.421 which represents an annual dividend yield of 3.92%. See more information on GlaxoSmithKline dividends here
What is GlaxoSmithKline’s EPS estimate?
GlaxoSmithKline’s EPS estimate is 1.15.
How many shares outstanding does GlaxoSmithKline have?
GlaxoSmithKline has 2,054,865,700 shares outstanding.
What happened to GlaxoSmithKline’s price movement after its last earnings report?
GlaxoSmithKline reported an EPS of $1.199 in its last earnings report, beating expectations of $1.045. Following the earnings report the stock price went up 2.258%.
Which hedge fund is a major shareholder of GlaxoSmithKline?
Currently, no hedge funds are holding shares in GSK
---
GlaxoSmithKline Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$40.08 (2.59% Upside)
$40.08 (2.59% Upside)
Blogger Sentiment
Bullish
GSK Sentiment 90%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 10.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days <0.1%
Last 30 Days ▲ 3.4%
Last 30 Days ▲ 3.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.30%
12-Months-Change
Fundamentals
Return on Equity
22.26%
Trailing 12-Months
Asset Growth
6.01%
Trailing 12-Months
Company Description
GlaxoSmithKline
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
---
GSK Company Deck
---
GSK Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong growth in specialty medicines and promising R&D advancements, positioning GSK for continued success. However, challenges such as declining vaccine sales, macroeconomic uncertainties, and impacts from Medicare Part D redesign were notable concerns. Despite these issues, the overall sentiment remains positive due to strategic growth areas and confident long-term outlooks.Read More>---
GSK Stock 12 Month Forecast
Average Price Target
$40.08
▲(2.59% Upside)
Technical Analysis
---